ProCE Banner Activity

Pembrolizumab + Carboplatin and Pemetrexed in Previously Untreated, Advanced Nonsquamous NSCLC: Updated Results From KEYNOTE-021 Cohort G

Slideset Download
Conference Coverage
Pembrolizumab plus chemotherapy significantly improved ORR and PFS vs chemotherapy alone with comparable safety profile.

Released: June 04, 2017

Expiration: June 03, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology